23,703 Shares in NewLink Genetics Corp (NLNK) Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd acquired a new stake in shares of NewLink Genetics Corp (NASDAQ:NLNK) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 23,703 shares of the biotechnology company’s stock, valued at approximately $241,000. Dynamic Technology Lab Private Ltd owned 0.06% of NewLink Genetics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Ameriprise Financial Inc. lifted its holdings in shares of NewLink Genetics by 207.1% during the third quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock valued at $3,176,000 after acquiring an additional 210,360 shares during the period. Candriam Luxembourg S.C.A. raised its holdings in shares of NewLink Genetics by 337.3% in the third quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock valued at $3,339,000 after buying an additional 253,000 shares during the last quarter. American Century Companies Inc. bought a new position in shares of NewLink Genetics in the third quarter valued at about $963,000. The Manufacturers Life Insurance Company raised its holdings in shares of NewLink Genetics by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 556 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of NewLink Genetics by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after buying an additional 4,630 shares during the last quarter. 52.66% of the stock is owned by institutional investors.

Shares of NewLink Genetics Corp (NLNK) opened at $7.89 on Thursday. NewLink Genetics Corp has a 12-month low of $5.90 and a 12-month high of $25.17.

NLNK has been the subject of a number of research analyst reports. Jefferies Group set a $7.00 price target on NewLink Genetics and gave the company a “hold” rating in a report on Friday, August 25th. ValuEngine cut NewLink Genetics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Robert W. Baird raised NewLink Genetics from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $8.00 to $22.00 in a report on Friday, September 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $26.00 price target on shares of NewLink Genetics in a report on Friday, September 8th. Finally, Stifel Nicolaus lifted their price target on NewLink Genetics from $14.00 to $29.00 and gave the company a “buy” rating in a report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $23.43.

In other news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the stock in a transaction that occurred on Friday, October 6th. The stock was purchased at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the completion of the transaction, the insider now directly owns 7,857,732 shares in the company, valued at $80,541,753. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.70% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “23,703 Shares in NewLink Genetics Corp (NLNK) Purchased by Dynamic Technology Lab Private Ltd” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.thestockobserver.com/2017/12/07/23703-shares-in-newlink-genetics-corp-nlnk-purchased-by-dynamic-technology-lab-private-ltd.html.

NewLink Genetics Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply